Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia.


Journal

ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 27 11 2020
accepted: 07 12 2020
entrez: 15 3 2021
pubmed: 16 3 2021
medline: 16 3 2021
Statut: epublish

Résumé

The relationship between early oseltamivir treatment (within 48 h of symptom onset) and mortality in patients admitted to intensive care units (ICUs) with severe influenza is disputed. This study aimed to investigate the association between early oseltamivir treatment and ICU mortality in critically ill patients with influenza pneumonia. This was an observational study of patients with influenza pneumonia admitted to 184 ICUs in Spain during 2009-2018. The primary outcome was to evaluate the association between early oseltamivir treatment and ICU mortality compared with later treatment. Secondary outcomes were to compare the duration of mechanical ventilation and ICU length of stay between the early and later oseltamivir treatment groups. To reduce biases related to observational studies, propensity score matching and a competing risk analysis were performed. During the study period, 2124 patients met the inclusion criteria. All patients had influenza pneumonia and received oseltamivir before ICU admission. Of these, 529 (24.9%) received early oseltamivir treatment. In the multivariate analysis, early treatment was associated with reduced ICU mortality (OR 0.69, 95% CI 0.51-0.95). After propensity score matching, early oseltamivir treatment was associated with improved survival rates in the Cox regression (hazard ratio 0.77, 95% CI 0.61-0.99) and competing risk (subdistribution hazard ratio 0.67, 95% CI 0.53-0.85) analyses. The ICU length of stay and duration of mechanical ventilation were shorter in patients receiving early treatment. Early oseltamivir treatment is associated with improved survival rates in critically ill patients with influenza pneumonia, and may decrease ICU length of stay and mechanical ventilation duration.

Sections du résumé

BACKGROUND BACKGROUND
The relationship between early oseltamivir treatment (within 48 h of symptom onset) and mortality in patients admitted to intensive care units (ICUs) with severe influenza is disputed. This study aimed to investigate the association between early oseltamivir treatment and ICU mortality in critically ill patients with influenza pneumonia.
METHODS METHODS
This was an observational study of patients with influenza pneumonia admitted to 184 ICUs in Spain during 2009-2018. The primary outcome was to evaluate the association between early oseltamivir treatment and ICU mortality compared with later treatment. Secondary outcomes were to compare the duration of mechanical ventilation and ICU length of stay between the early and later oseltamivir treatment groups. To reduce biases related to observational studies, propensity score matching and a competing risk analysis were performed.
RESULTS RESULTS
During the study period, 2124 patients met the inclusion criteria. All patients had influenza pneumonia and received oseltamivir before ICU admission. Of these, 529 (24.9%) received early oseltamivir treatment. In the multivariate analysis, early treatment was associated with reduced ICU mortality (OR 0.69, 95% CI 0.51-0.95). After propensity score matching, early oseltamivir treatment was associated with improved survival rates in the Cox regression (hazard ratio 0.77, 95% CI 0.61-0.99) and competing risk (subdistribution hazard ratio 0.67, 95% CI 0.53-0.85) analyses. The ICU length of stay and duration of mechanical ventilation were shorter in patients receiving early treatment.
CONCLUSIONS CONCLUSIONS
Early oseltamivir treatment is associated with improved survival rates in critically ill patients with influenza pneumonia, and may decrease ICU length of stay and mechanical ventilation duration.

Identifiants

pubmed: 33718494
doi: 10.1183/23120541.00888-2020
pii: 00888-2020
pmc: PMC7938052
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright ©ERS 2021.

Déclaration de conflit d'intérêts

Conflict of interest: G. Moreno has nothing to disclose. Conflict of interest: A. Rodríguez has nothing to disclose. Conflict of interest: J. Sole-Violán has nothing to disclose. Conflict of interest: I. Martín-Loeches has nothing to disclose. Conflict of interest: E. Díaz has nothing to disclose. Conflict of interest: M. Bodí has nothing to disclose. Conflict of interest: L.F. Reyes has nothing to disclose. Conflict of interest: J. Gómez has nothing to disclose. Conflict of interest: J. Guardiola has nothing to disclose. Conflict of interest: S. Trefler has nothing to disclose. Conflict of interest: L. Vidaur has nothing to disclose. Conflict of interest: E. Papiol has nothing to disclose. Conflict of interest: L. Socias has nothing to disclose. Conflict of interest: C. García-Vidal reports grants and other support from Gilead Science and Merck Sharp & Dohme, and other support from Novartis, Pfizer, Janssen and Lilly, outside the submitted work. Conflict of interest: E. Correig has nothing to disclose. Conflict of interest: J. Marín-Corral has nothing to disclose. Conflict of interest: M.I. Restrepo has nothing to disclose. Conflict of interest: J.S. Nguyen-Van-Tam reports grants from F. Hoffmann-La Roche, outside the submitted work. He was seconded to the Dept of Health and Social Care (DHSC) England in 2017; the views in this article are those of the authors and not necessarily those of the DHSC. Conflict of interest: A. Torres has nothing to disclose.

Références

Chest. 2011 Feb;139(2):382-386
pubmed: 20688928
Expert Rev Clin Pharmacol. 2017 Jan;10(1):81-95
pubmed: 27797595
Crit Care. 2019 Jan 3;23(1):1
pubmed: 30606235
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Eur Respir J. 2015 Jun;45(6):1642-52
pubmed: 25573405
JAMA. 2009 Nov 4;302(17):1880-7
pubmed: 19822626
PLoS One. 2009 Jun 25;4(6):e6051
pubmed: 19557130
Med Intensiva. 2012 Mar;36(2):103-37
pubmed: 22245450
Eur J Clin Microbiol Infect Dis. 2018 Feb;37(2):319-323
pubmed: 29143145
Intensive Care Med. 2017 Jan;43(1):48-58
pubmed: 27709265
Intensive Care Med. 2018 Sep;44(9):1470-1482
pubmed: 30074052
Crit Care. 2006 Feb;10(1):R5
pubmed: 16356211
Clin Infect Dis. 2011 Feb 15;52(4):457-65
pubmed: 21220768
Intensive Care Med. 2020 Feb;46(2):315-328
pubmed: 32040667
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Clin Infect Dis. 2012 Nov;55(9):1198-204
pubmed: 22843781
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Curr Opin Pulm Med. 2020 May;26(3):215-221
pubmed: 32068576
Intensive Care Med. 2020 Feb;46(2):153-162
pubmed: 31912206
Clin Infect Dis. 2019 Jun 18;69(1):52-58
pubmed: 30304487
Clin Infect Dis. 2019 Nov 13;69(11):1896-1902
pubmed: 30753349
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
N Engl J Med. 2009 Nov 12;361(20):1935-44
pubmed: 19815859
Clin Infect Dis. 2019 Mar 5;68(6):e1-e47
pubmed: 30566567
JAMA Intern Med. 2015 Dec;175(12):1899-900
pubmed: 26501509
Mayo Clin Proc Innov Qual Outcomes. 2020 Apr 06;4(2):176-182
pubmed: 32280928
Bull World Health Organ. 2018 Feb 1;96(2):122-128
pubmed: 29403115
J Antimicrob Chemother. 2011 May;66(5):959-63
pubmed: 21406435
Crit Care. 2011;15(6):R286
pubmed: 22126648
Stat Med. 2015 Dec 30;34(30):3949-67
pubmed: 26250611
J Clin Epidemiol. 2017 Apr;84:121-129
pubmed: 28188897
Lancet Respir Med. 2014 May;2(5):395-404
pubmed: 24815805
Lancet. 2013 Jun 29;381(9885):2273-9
pubmed: 23726392
Am J Epidemiol. 2008 Apr 1;167(7):775-85
pubmed: 18230677
Clin Infect Dis. 2010 Apr 1;50(7):963-9
pubmed: 20180701
J Crit Care. 2016 Dec;36:195-199
pubmed: 27546771
J Antimicrob Chemother. 2011 May;66(5):1140-9
pubmed: 21385717
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
Influenza Other Respir Viruses. 2016 May;10(3):192-204
pubmed: 26602067
Clin Infect Dis. 2014 Jul 15;59(2):252-5
pubmed: 24748521

Auteurs

Gerard Moreno (G)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.
These authors contributed equally.

Alejandro Rodríguez (A)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.
These authors contributed equally.

Jordi Sole-Violán (J)

Critical Care Dept, Hospital Universitario de Gran Canaria Dr Negrín, CIBERES, Las Palmas de Gran Canaria, Spain.

Ignacio Martín-Loeches (I)

Dept of Anaesthesia and Critical Care, St James's University Hospital, Trinity Centre for Health Sciences, Multidisciplinary Intensive Care Research Organisation (MICRO), Dublin, Ireland.

Emili Díaz (E)

Critical Care Dept, Hospital Parc Taulí, CIBERES, Sabadell, Spain.

María Bodí (M)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.

Luis F Reyes (LF)

Microbiology Dept, Universidad de La Sabana, Bogotá, Colombia.

Josep Gómez (J)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.

Juan Guardiola (J)

Division of Pulmonary, Critical Care and Sleep Medicine, University of Louisville and Robley Rex VA Medical Center, Louisville, KY, USA.

Sandra Trefler (S)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.

Loreto Vidaur (L)

Critical Care Dept, Hospital Universitario Donostia, San Sebastián, Spain.

Elisabet Papiol (E)

Critical Care Dept, Hospital Vall d'Hebrón, Barcelona, Spain.

Lorenzo Socias (L)

Critical Care Dept, Hospital Son Llàtzer, Palma de Mallorca, Spain.

Carolina García-Vidal (C)

Infectious Diseases, Hospital Clínic de Barcelona, Barcelona, Spain.

Eudald Correig (E)

Critical Care Dept, Hospital Universitari de Tarragona Joan XXIII, URV/IISPV/CIBERES, Tarragona, Spain.

Judith Marín-Corral (J)

Critical Care Dept, Hospital Del Mar, Research Group in Critical Disorders (GREPAC), IMIM, Barcelona, Spain.

Marcos I Restrepo (MI)

South Texas Veterans Health Care System, University of Texas Health Sciences at San Antonio, San Antonio, TX, USA.

Jonathan S Nguyen-Van-Tam (JS)

Health Protection and Influenza Research Group, Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK.

Antoni Torres (A)

Servei de Pneumologia i Al·lèrgia Respiratòria, Institut Clínic del Tórax, Hospital Clínic de Barcelona, CIBERES, Barcelona, Spain.
GETGAG Study Group Investigators are listed in the supplementary material.

Classifications MeSH